TSLA
Tesla
-- 421.060 PLTR
Palantir
-- 80.550 NVDA
NVIDIA
-- 134.700 OXY
Occidental Petroleum
-- 47.130 AMD
Advanced Micro Devices
-- 119.210 
Even better!
$Cogent Biosciences (COGT.US)$ Cogent Biosciences (COGT) said Thursday that new lead-in data from ongoing phase 3 trial of a combination of bezuclastinib and sunitinib showed potential to become new standard of care for advanced gastrointestinal stromal tumors, a type of cancer.
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activity demonstrated by the combination, the addition of bezuclastinib to sunitinib continues to be generally well-tolerated with an encouraging safety profile," Cogent Chief Executive Andrew Robbins said.
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activity demonstrated by the combination, the addition of bezuclastinib to sunitinib continues to be generally well-tolerated with an encouraging safety profile," Cogent Chief Executive Andrew Robbins said.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : I remember detecting a gastro CA as young as 25, referred to onco after CT, and such aggressiveness killed him in less than a year.
Trytosaveabit OP Jaguar8 : So sad! If it woulda been found sooner could a bit more time been had? Or in this case it wouldn’t have made a difference?
Jaguar8 Trytosaveabit OP : This type of cancer is usually diagnosed in advanced stage and a very aggressive one
Trytosaveabit OP Jaguar8 : Yeah! Sad! BTW all the BIO PR released this evening! I’m really digging the INAB especially with how close they seem to be getting to end of phase?
Jaguar8 Trytosaveabit OP : Yes INAB study is very interesting!